Epilepsy and Deep Brain Stimulation of Anterior Thalamic Nucleus

Presently, at least 60 million people are suffering from epilepsy worldwide. Although multiple pharmacological options for treatment exist, about 30% to 40% of these patients estimated have drug-resistant (DRE), which is associated with severe disability and morbidity. The surgical restricted either open procedures or laser ablations. When a resective option not favorable, then neuromodulation such as vagal nerve stimulation deep brain considered. A relatively recent more commonly used clinical application the (DBS) anterior thalamic nucleus, FDA approval was obtained in 2018. Furthermore, new technological advances DBS technology expected positively impact patients.